June 1, 2019

Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study

PUBLICATION: 
Breast Cancer Res Treat. (2019) 175: 389. https://doi.org/10.1007/s10549-018-05075-x.

AUTHORS: 
R. Wuerstlein, R. Kates, O. Gluz, E.M. Grischke, C. Schem, M. Thill, S. Hasmueller, A. Köhler, B. Otremba, F. Griesinger, C. Schindlbeck, A. Trojan, F. Otto, M. Knauer, R. Pusch, N. Harbeck, WSG-PRIMe investigators in Germany, Austria, Switzerland

SUMMARY: 
MammaPrint and BluePrint test results strongly impacted physicians’ therapy decisions in luminal EBC with up to three involved lymph nodes. The high adherence to genetically determined risk assessment represents a key prerequisite for achieving a personalized cost-effective approach to disease management of early breast cancer.

Read more: Wuerstlein et al_2019_Breast Cancer Res Treat._Strong Impact of MammaPrint and BluePrint…